Replies to post #3897 on GTC Biotherapeutics (fka GTCB)

[ThomasS]

Biosimiliars: my question/concern is whether or not transgenically-derived biosimiliars, if that is where GTC is pointed, are going to have a greater headwind than other biosimiliars?

[aslan2772]

Re: Biosimilars

I hope GTCB investors realize how exciting this topic is for GTCB.

If anyone wants to shell out the dough for this article, I'd love to hear your synopsis ;)

"Biosimilar developers turn to the USP to help find a way to accelerate the development of a regulatory pathway for biosimilars of NDA biologics by characterizing comparability between biosimilars and innovator biologics"

http://www.leaddiscovery.co.uk/reports/pharmaceutical-reports-markets-and-pipelines/biosimilars_regu....